Key Inclusion Criteria:  Participant with clinical diagnosis of acne vulgaris, defined by:  moderate acne on the face (acne Investigator's Global Assessment [IGA] =3); and with minimum of 20 inflammatory lesions and 25 non inflammatory lesions on the face (excluding the nose); and moderate to marked PIH on the face (Overview of Pigmentation Disorders [ODS] hyperpigmentation scale 4-6); and no more than one acne nodule or cyst (greater than [>] 1 centimeter [cm]) on face (excluding the nose) Participant with any Fitzpatrick Skin Type I to VI (target patient enrollment according to FST) Female participants of childbearing potential must have a negative urine pregnancy test (UPT) at Baseline visit Female participants of childbearing potential must agree to use an adequate and approved method of contraception throughout the study Female participant of non-childbearing potential Other protocol defined inclusion criteria could apply  Key Exclusion Criteria:  Participant with severe acne (IGA > 3) Participant with more than 1 nodule/cyst on the face (excluding the nose) Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne, acne requiring systemic treatment Participant with damaged facial skin that may interfere with study assessments Female participant who is pregnant, lactating or planning a pregnancy during the study Female participant of childbearing potential using combined oral contraceptives approved as acne treatments, in whom the dose has not been stable for at least 6 months prior to the Baseline visit Participant with known impaired hepatic or renal functions Participant with active or chronic skin allergies